Barclays’s Aldeyra Therapeutics ALDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.7K | Sell |
9,906
-74,565
| -88% | -$327K | ﹤0.01% | 4608 |
|
|
2025
Q4 | $438K | Buy |
84,471
+7,827
| +10% | +$40.2K | ﹤0.01% | 3922 |
|
|
2025
Q3 | $400K | Sell |
76,644
-19,004
| -20% | -$99.1K | ﹤0.01% | 3940 |
|
|
2025
Q2 | $366K | Buy |
95,648
+44,691
| +88% | +$116K | ﹤0.01% | 3931 |
|
|
2025
Q1 | $293K | Sell |
50,957
-24,373
| -32% | -$144K | ﹤0.01% | 3846 |
|
|
2024
Q4 | $376K | Buy |
75,330
+9,769
| +15% | +$50.1K | ﹤0.01% | 3996 |
|
|
2024
Q3 | $353K | Buy |
65,561
+48,313
| +280% | +$230K | ﹤0.01% | 3980 |
|
|
2024
Q2 | $57.1K | Sell |
17,248
-15,239
| -47% | -$59.7K | ﹤0.01% | 4155 |
|
|
2024
Q1 | $106K | Sell |
32,487
-31,368
| -49% | -$103K | ﹤0.01% | 4409 |
|
|
2023
Q4 | $224K | Sell |
63,855
-74,456
| -54% | -$230K | ﹤0.01% | 4365 |
|
|
2023
Q3 | $924K | Buy |
138,311
+11,447
| +9% | +$84.9K | ﹤0.01% | 2385 |
|
|
2023
Q2 | $1.06M | Buy |
126,864
+110,039
| +654% | +$1.08M | ﹤0.01% | 2261 |
|
|
2023
Q1 | $167K | Sell |
16,825
-12,954
| -44% | -$91.6K | ﹤0.01% | 3896 |
|
|
2022
Q4 | $207K | Buy |
29,779
+20,844
| +233% | +$119K | ﹤0.01% | 3819 |
|
|
2022
Q3 | $48K | Buy |
+8,935
| New | +$53.6K | ﹤0.01% | 3789 |
|
|
2022
Q2 | – | Sell |
-150,981
| Closed | -$671K | – | 4998 |
|
|
2022
Q1 | $671K | Buy |
150,981
+92,072
| +156% | +$367K | ﹤0.01% | 2693 |
|
|
2021
Q4 | $236K | Buy |
58,909
+15,028
| +34% | +$115K | ﹤0.01% | 3504 |
|
|
2021
Q3 | $386K | Buy |
43,881
+15,186
| +53% | +$139K | ﹤0.01% | 3311 |
|
|
2021
Q2 | $325K | Sell |
28,695
-22,050
| -43% | -$265K | ﹤0.01% | 3311 |
|
|
2021
Q1 | $603K | Buy |
+50,745
| New | +$584K | ﹤0.01% | 3077 |
|
|
2020
Q3 | – | Sell |
-6,451
| Closed | -$27K | – | 5183 |
|
|
2020
Q2 | $27K | Sell |
6,451
-1,170
| -15% | -$4.27K | ﹤0.01% | 5131 |
|
|
2020
Q1 | $19K | Sell |
7,621
-15,305
| -67% | -$68.8K | ﹤0.01% | 5652 |
|
|
2019
Q4 | $133K | Buy |
22,926
+11,737
| +105% | +$67.8K | ﹤0.01% | 5308 |
|
|
2019
Q3 | $59K | Sell |
11,189
-3,352
| -23% | -$18K | ﹤0.01% | 5816 |
|
|
2019
Q2 | $87K | Buy |
14,541
+6,342
| +77% | +$47.7K | ﹤0.01% | 5785 |
|
|
2019
Q1 | $74K | Buy |
8,199
+1,759
| +27% | +$14.9K | ﹤0.01% | 5591 |
|
|
2018
Q4 | $53K | Buy |
6,440
+73
| +1% | +$748 | ﹤0.01% | 5439 |
|
|
2018
Q3 | $88K | Buy |
6,367
+5,199
| +445% | +$42.2K | ﹤0.01% | 5669 |
|
|
2018
Q2 | $9K | Buy |
1,168
+1,167
| +116,700% | +$9.31K | ﹤0.01% | 6563 |
|
|
2018
Q1 | $0 | Buy |
+1
| New | +$8 | ﹤0.01% | 7015 |
|
|
2017
Q4 | – | Sell |
-3,400
| Closed | -$24K | – | 6900 |
|
|
2017
Q3 | $24K | Buy |
+3,400
| New | +$17.8K | ﹤0.01% | 5710 |
|
Other funds holding ALDX
KCM
VCM
KCM
6CM
Barclays's ALDX Position: Q1 2026 in Review
Barclays reduced its Aldeyra Therapeutics (ALDX) stake by 88% in Q1 2026, selling an estimated $327K and leaving 9,906 shares worth $16.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4608.
Barclays first reported a position in ALDX in Q3 2017 and has held it in 31 quarters since. The position peaked at $1.06M in Q2 2023. 128 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.
- Barclays held 9,906 shares of Aldeyra Therapeutics worth $16.7K as of Q1 2026.
- Barclays sold 74,565 Aldeyra Therapeutics shares in Q1 2026, an estimated $327K.
- Aldeyra Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4608 holding.
- Barclays first reported a position in Aldeyra Therapeutics in Q3 2017 and has held it in 31 quarters since.
- Barclays's Aldeyra Therapeutics position peaked at $1.06M in Q2 2023.
- 128 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.